Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR150106XB in active rheumatoid arthritis
2007-000760-24Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SSR150106 in rheumatoid arthritis (RA) (3 arms), sponsored by Sanofi. Primary endpoint: Change in mean C-reactive protein level. Started May 2007; status: completed.
02
Drugs
SSR150106
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-000760-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000760-24.